ESC 365 - How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study.

EHRA Premium Access

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study.

Session: Atrial Fibrillation - Round 1 - Stroke - OAC

Topic: Oral Anticoagulation

Speaker: Doctor M. Lehto (Helsinki, FI)

Event: EHRA 2023

Congress Presentation

Add to my library

About the speaker

Doctor Mika Lehto

Helsinki University Hospital, Helsinki (Finland)

0 follower

7 more presentations in this session

5 years incident stroke, heart failure, acute myocardial infarction, and death in patients having undergone atrial fibrillation ablation according to BMI

Speaker: Doctor J. Toennesen (Gentofte, DK)

Statin use improves the outcomes in patients with atrial fibrillation: A population-based study

Speaker: Miss J. Huang (Hong Kong, HK)

Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke

Speaker: Doctor L. Xing (Copenhagen, DK)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study

Speaker: Mr M. Grymonprez (Gent, BE)

Racial differences in atrial fibrillation-related bleeding and mortality.

Speaker: Doctor K. Dongseon (Seoul, KR)

Access the full session

Atrial Fibrillation - Round 1 - Stroke - OAC

Speakers: Doctor M. Lehto, Doctor J. Toennesen, Miss J. Huang, Doctor L. Xing, Mr M. Grymonprez...

About the event

EHRA 2023

16 April - 18 April 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources